Pharmacist Assisted Medication Program Enhancing the Regulation of Diabetes

NACompletedINTERVENTIONAL
Enrollment

285

Participants

Timeline

Start Date

September 30, 2000

Study Completion Date

July 31, 2004

Conditions
Diabetes Mellitus, Type 2
Interventions
OTHER

Pharmacist collaboration in diabetes care

Patients attended a minimum of 3 clinic visits (month 0, 6, 12) with one of the clinical pharmacists, where targeted physical assessment, education, and medication changes and follow up were recommended. Additional visits were arranged as clinically appropriate for drug monitoring. Referrals were facilitated to other clinicians where indicated, including ophthalmology, podiatry, CDEs, nutrition, and primary care. The pharmacists' recommendations for medication adjustment, laboratory monitoring and referrals were based upon the most recent guidelines and clinical trial evidence. Any therapy adjustment, lab testing or referrals required approval by the referring physician. A1c, lipid and BP values were collected prospectively at months 0, 6 and 12.

OTHER

Usual care

Control patients received usual care directed by their physician, and the same data were gathered from chart review during the 12-month study period.

Trial Locations (1)

01805

Lahey Clinic, Burlington

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

Lahey Clinic

OTHER

NCT00541606 - Pharmacist Assisted Medication Program Enhancing the Regulation of Diabetes | Biotech Hunter | Biotech Hunter